FLT3 (Japanese Wikipedia)

Analysis of information sources in references of the Wikipedia article "FLT3" in Japanese language version.

Last modified: 16:05:07, 27 November 2023 (UTC)

Ref.Un. Ref.Website

Global rank Japanese rank

1313nih.gov

5^th place

11^th place

88doi.org

2^nd place

3^rd place

62ensembl.org

630^th place

1,132^nd place

43fda.gov

470^th place

943^rd place

21web.archive.org

1^st place

21sabiosciences.com

low place

11lib4ri.ch

low place

11atlasgeneticsoncology.org

low place

11cancertherapyadvisor.com

low place

11semanticscholar.org

15^th place

750^th place

11adsabs.harvard.edu

14^th place

60^th place

adsabs.harvard.edu (Global: 14^th place; Japanese: 60^th place)

ui.adsabs.harvard.edu

Smith CC, Wang Q, Chin CS, Salerno S, Damon LE, Levis MJ, et al. (April 2012). “Validation of ITD mutations in FLT3 as a therapeutic target in human acute myeloid leukaemia”. Nature. 485 (7397): 260–3. Bibcode:2012Natur.485..260S. doi:10.1038/nature11016. PMC 3390926. PMID 22504184.

atlasgeneticsoncology.org (Global: low place; Japanese: low place)

Huret J-L. “FLT3 (FMS-like tyrosine kinase 3)”. Atlas of Genetics and Cytogenetics in Oncology and Haematology. University Hospital of Poitiers. 2023年8月5日閲覧。

cancertherapyadvisor.com (Global: low place; Japanese: low place)

“Gilteritinib Granted Orphan Drug Status for Acute Myeloid Leukemia” (2017年7月20日). 2023年8月5日閲覧。

doi.org (Global: 2^nd place; Japanese: 3^rd place)

Yamamoto Y, Kiyoi H, Nakano Y, Suzuki R, Kodera Y, Miyawaki S, Asou N, Kuriyama K, Yagasaki F, Shimazaki C, Akiyama H, Saito K, Nishimura M, Motoji T, Shinagawa K, Takeshita A, Saito H, Ueda R, Ohno R, Naoe T (April 2001). “Activating mutation of D835 within the activation loop of FLT3 in human hematologic malignancies”. Blood. 97 (8): 2434–9. doi:10.1182/blood.V97.8.2434. PMID 11290608.
Verstraete K, Vandriessche G, Januar M, Elegheert J, Shkumatov AV, Desfosses A, Van Craenenbroeck K, Svergun DI, Gutsche I, Vergauwen B, Savvides SN (February 2011). “Structural insights into the extracellular assembly of the hematopoietic Flt3 signaling complex”. Blood. 118 (1): 60–68. doi:10.1182/blood-2011-01-329532. PMID 21389326.
Mooney CJ, Cunningham A, Tsapogas P, Toellner KM, Brown G. Selective Expression of Flt3 within the Mouse Hematopoietic Stem Cell Compartment. Int J Mol Sci. 2017 May 12;18(5):1037. doi:10.3390/ijms18051037 . PMID 28498310; PMC 5454949.
Chew S, Mackey MC, Jabbour E (2020). “Gilteritinib in the treatment of relapsed and refractory acute myeloid leukemia with a FLT3 mutation”. Review. Therapeutic Advances in Hematology. 11: 2040620720930614. doi:10.1177/2040620720930614. PMC 7271272. PMID 32547718.{{cite journal2}}: CS1メンテナンス: ページ番号として指定されている記事番号 (カテゴリ)
Perl AE, Martinelli G, Cortes JE, Neubauer A, Berman E, Paolini S, et al. (October 2019). “FLT3-Mutated AML”. The New England Journal of Medicine. 381 (18): 1728–1740. doi:10.1056/NEJMoa1902688. PMID 31665578.
Metzelder S, Wang Y, Wollmer E, Wanzel M, Teichler S, Chaturvedi A, Eilers M, Enghofer E, Neubauer A, Burchert A (June 2009). “Compassionate use of sorafenib in FLT3-ITD-positive acute myeloid leukemia: sustained regression before and after allogeneic stem cell transplantation”. Blood. 113 (26): 6567–71. doi:10.1182/blood-2009-03-208298. PMID 19389879. S2CID 206878993.
Zhang W, Konopleva M, Shi YX, McQueen T, Harris D, Ling X, Estrov Z, Quintás-Cardama A, Small D, Cortes J, Andreeff M (February 2008). “Mutant FLT3: a direct target of sorafenib in acute myelogenous leukemia”. J. Natl. Cancer Inst. 100 (3): 184–98. doi:10.1093/jnci/djm328. PMID 18230792.
Smith CC, Wang Q, Chin CS, Salerno S, Damon LE, Levis MJ, et al. (April 2012). “Validation of ITD mutations in FLT3 as a therapeutic target in human acute myeloid leukaemia”. Nature. 485 (7397): 260–3. Bibcode:2012Natur.485..260S. doi:10.1038/nature11016. PMC 3390926. PMID 22504184.

ensembl.org (Global: 630^th place; Japanese: 1,132^nd place)

may2017.archive.ensembl.org

GRCh38: Ensembl release 89: ENSG00000122025 - Ensembl, May 2017
GRCm38: Ensembl release 89: ENSMUSG00000042817 - Ensembl, May 2017

fda.gov (Global: 470^th place; Japanese: 943^rd place)

“FDA approves gilteritinib for relapsed or refractory acute myeloid leukemia (AML) with a FLT3 mutatation”. Drugs. FDA (2018年12月14日). 2023年7月21日閲覧。
“FDA approves quizartinib for newly diagnosed acute myeloid leukemia”. Drugs. FDA (2023年7月20日). 2023年7月21日閲覧。
Office of the Commissioner. “Press Announcements - FDA approves new combination treatment for acute myeloid leukemia” (英語). www.fda.gov. 2017年5月4日閲覧。

lib4ri.ch (Global: low place; Japanese: low place)

dora.lib4ri.ch

Verstraete K, Vandriessche G, Januar M, Elegheert J, Shkumatov AV, Desfosses A, Van Craenenbroeck K, Svergun DI, Gutsche I, Vergauwen B, Savvides SN (February 2011). “Structural insights into the extracellular assembly of the hematopoietic Flt3 signaling complex”. Blood. 118 (1): 60–68. doi:10.1182/blood-2011-01-329532. PMID 21389326.

nih.gov (Global: 5^th place; Japanese: 11^th place)

pubmed.ncbi.nlm.nih.gov

Yamamoto Y, Kiyoi H, Nakano Y, Suzuki R, Kodera Y, Miyawaki S, Asou N, Kuriyama K, Yagasaki F, Shimazaki C, Akiyama H, Saito K, Nishimura M, Motoji T, Shinagawa K, Takeshita A, Saito H, Ueda R, Ohno R, Naoe T (April 2001). “Activating mutation of D835 within the activation loop of FLT3 in human hematologic malignancies”. Blood. 97 (8): 2434–9. doi:10.1182/blood.V97.8.2434. PMID 11290608.
Verstraete K, Vandriessche G, Januar M, Elegheert J, Shkumatov AV, Desfosses A, Van Craenenbroeck K, Svergun DI, Gutsche I, Vergauwen B, Savvides SN (February 2011). “Structural insights into the extracellular assembly of the hematopoietic Flt3 signaling complex”. Blood. 118 (1): 60–68. doi:10.1182/blood-2011-01-329532. PMID 21389326.
Mooney CJ, Cunningham A, Tsapogas P, Toellner KM, Brown G. Selective Expression of Flt3 within the Mouse Hematopoietic Stem Cell Compartment. Int J Mol Sci. 2017 May 12;18(5):1037. doi:10.3390/ijms18051037 . PMID 28498310; PMC 5454949.
Chew S, Mackey MC, Jabbour E (2020). “Gilteritinib in the treatment of relapsed and refractory acute myeloid leukemia with a FLT3 mutation”. Review. Therapeutic Advances in Hematology. 11: 2040620720930614. doi:10.1177/2040620720930614. PMC 7271272. PMID 32547718.{{cite journal2}}: CS1メンテナンス: ページ番号として指定されている記事番号 (カテゴリ)
Perl AE, Martinelli G, Cortes JE, Neubauer A, Berman E, Paolini S, et al. (October 2019). “FLT3-Mutated AML”. The New England Journal of Medicine. 381 (18): 1728–1740. doi:10.1056/NEJMoa1902688. PMID 31665578.
Metzelder S, Wang Y, Wollmer E, Wanzel M, Teichler S, Chaturvedi A, Eilers M, Enghofer E, Neubauer A, Burchert A (June 2009). “Compassionate use of sorafenib in FLT3-ITD-positive acute myeloid leukemia: sustained regression before and after allogeneic stem cell transplantation”. Blood. 113 (26): 6567–71. doi:10.1182/blood-2009-03-208298. PMID 19389879. S2CID 206878993.
Zhang W, Konopleva M, Shi YX, McQueen T, Harris D, Ling X, Estrov Z, Quintás-Cardama A, Small D, Cortes J, Andreeff M (February 2008). “Mutant FLT3: a direct target of sorafenib in acute myelogenous leukemia”. J. Natl. Cancer Inst. 100 (3): 184–98. doi:10.1093/jnci/djm328. PMID 18230792.
Smith CC, Wang Q, Chin CS, Salerno S, Damon LE, Levis MJ, et al. (April 2012). “Validation of ITD mutations in FLT3 as a therapeutic target in human acute myeloid leukaemia”. Nature. 485 (7397): 260–3. Bibcode:2012Natur.485..260S. doi:10.1038/nature11016. PMC 3390926. PMID 22504184.

ncbi.nlm.nih.gov

Human PubMed Reference:
Mouse PubMed Reference:
Mooney CJ, Cunningham A, Tsapogas P, Toellner KM, Brown G. Selective Expression of Flt3 within the Mouse Hematopoietic Stem Cell Compartment. Int J Mol Sci. 2017 May 12;18(5):1037. doi:10.3390/ijms18051037 . PMID 28498310; PMC 5454949.
Chew S, Mackey MC, Jabbour E (2020). “Gilteritinib in the treatment of relapsed and refractory acute myeloid leukemia with a FLT3 mutation”. Review. Therapeutic Advances in Hematology. 11: 2040620720930614. doi:10.1177/2040620720930614. PMC 7271272. PMID 32547718.{{cite journal2}}: CS1メンテナンス: ページ番号として指定されている記事番号 (カテゴリ)
Smith CC, Wang Q, Chin CS, Salerno S, Damon LE, Levis MJ, et al. (April 2012). “Validation of ITD mutations in FLT3 as a therapeutic target in human acute myeloid leukaemia”. Nature. 485 (7397): 260–3. Bibcode:2012Natur.485..260S. doi:10.1038/nature11016. PMC 3390926. PMID 22504184.

sabiosciences.com (Global: low place; Japanese: low place)

“FLT3 Signaling”. Pathway Central. SABiosciences. 2017年11月11日時点のオリジナルよりアーカイブ。2012年12月18日閲覧。

semanticscholar.org (Global: 15^th place; Japanese: 750^th place)

api.semanticscholar.org

Metzelder S, Wang Y, Wollmer E, Wanzel M, Teichler S, Chaturvedi A, Eilers M, Enghofer E, Neubauer A, Burchert A (June 2009). “Compassionate use of sorafenib in FLT3-ITD-positive acute myeloid leukemia: sustained regression before and after allogeneic stem cell transplantation”. Blood. 113 (26): 6567–71. doi:10.1182/blood-2009-03-208298. PMID 19389879. S2CID 206878993.

web.archive.org (Global: 1^st place; Japanese: 1^st place)

“FLT3 Signaling”. Pathway Central. SABiosciences. 2017年11月11日時点のオリジナルよりアーカイブ。2012年12月18日閲覧。

FLT3 (Japanese Wikipedia)

adsabs.harvard.edu (Global: 14th place; Japanese: 60th place)

ui.adsabs.harvard.edu

atlasgeneticsoncology.org (Global: low place; Japanese: low place)

cancertherapyadvisor.com (Global: low place; Japanese: low place)

doi.org (Global: 2nd place; Japanese: 3rd place)

ensembl.org (Global: 630th place; Japanese: 1,132nd place)

may2017.archive.ensembl.org

fda.gov (Global: 470th place; Japanese: 943rd place)

lib4ri.ch (Global: low place; Japanese: low place)

dora.lib4ri.ch

nih.gov (Global: 5th place; Japanese: 11th place)

pubmed.ncbi.nlm.nih.gov

ncbi.nlm.nih.gov

sabiosciences.com (Global: low place; Japanese: low place)

semanticscholar.org (Global: 15th place; Japanese: 750th place)

api.semanticscholar.org

web.archive.org (Global: 1st place; Japanese: 1st place)

adsabs.harvard.edu (Global: 14^th place; Japanese: 60^th place)

doi.org (Global: 2^nd place; Japanese: 3^rd place)

ensembl.org (Global: 630^th place; Japanese: 1,132^nd place)

fda.gov (Global: 470^th place; Japanese: 943^rd place)

nih.gov (Global: 5^th place; Japanese: 11^th place)

semanticscholar.org (Global: 15^th place; Japanese: 750^th place)

web.archive.org (Global: 1^st place; Japanese: 1^st place)